A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study

Y. Chiu, C. Tang, S. Hung, Y. Yang, C. Fang, H. Lin

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Search results